IV Cannula manufacturer wins duty exemption appeal, Tribunal cites Notification No. 6/03-CE, List 37, stresses cross-examination importance.

The Tribunal allowed the appeals, quashing duty demands against the appellant company for manufacturing IV Cannula under the brands Venflon and Neoflon. It held that the IV Cannula qualified for duty exemption under Notification No. 6/03-CE and its successor notifications, as they fell under the exemption entry in List 37 of Notification No. 21/02-CUS. The Tribunal emphasized the binding nature of the interpretation in a previous case, stressing the importance of allowing cross-examination of the DGHS official.

---

---

Issues Involved:
1. Eligibility for duty exemption under Notification No. 6/03-CE and its successor notifications.
2. Interpretation of the exemption entry in List 37 of Notification No. 21/02-CUS.
3. Validity of the Department's reliance on the opinion of Dr. P. Ravindran from DGHS.
4. Applicability of the doctrine of merger and stare decisis.
5. Requirement of cross-examination of the DGHS official.
6. Limitation period and applicability of Section 11AC.

Detailed Analysis:

1. Eligibility for Duty Exemption:
The appellant company manufactures IV Cannula under the brand names Venflon and Neoflon. They claimed exemption from Central Excise duty under Notification No. 6/03-CE and its successor notifications, which exempted medical equipment specified in List 37 of Notification No. 21/02-CUS. The Department issued multiple show cause notices and confirmed duty demands, arguing that the IV Cannula did not qualify for the exemption as they were not meant for aorta, vena cavae, or similar veins and blood vessels.

2. Interpretation of Exemption Entry:
The primary dispute was whether the exemption entry "Disposable and non-disposable Cannula for aorta, vena cavae and similar veins and blood vessels and Cannula for intra-corporal spaces" covered the IV Cannula manufactured by the appellant. The appellant argued that the term "blood vessels" should be read independently of "similar veins," thus covering their product. They relied on the Tribunal's decision in CCE, Coimbatore vs. Saberwal Surgical (P) Ltd., which held that the term "blood vessels" in a similar exemption entry was not qualified by "similar" and thus should be read independently.

3. Validity of DGHS Opinion:
The Department relied on the opinion of Dr. P. Ravindran from DGHS, who stated that the IV Cannula were primarily used in peripheral veins and arteries and could not be treated as Cannula for aorta, vena cavae, or similar veins and blood vessels. The appellant contended that the opinion was not binding and that cross-examination of Dr. Ravindran was necessary to challenge his findings.

4. Doctrine of Merger and Stare Decisis:
The appellant argued that the Tribunal's decision in Saberwal Surgical, which was affirmed by the Supreme Court, should be treated as a binding precedent due to the doctrine of merger. The Supreme Court's dismissal of the civil appeal against the Tribunal's order, even without detailed reasons, entailed the application of stare decisis, making the Tribunal's interpretation of the exemption entry binding.

5. Cross-Examination Requirement:
The appellant argued that the entire case against them was based on Dr. Ravindran's opinion, and without allowing his cross-examination, the opinion could not be acted upon. The Tribunal agreed that denying cross-examination vitiated the proceedings, as it was crucial to determine the validity of the DGHS opinion.

6. Limitation Period and Section 11AC:
The appellant claimed a bona fide belief in their eligibility for exemption based on the Tribunal's earlier decision, which justified not invoking the longer limitation period under Section 11A (1) and not imposing penalties under Section 11AC. The Tribunal accepted this argument, noting that the appellant had a reasonable basis for their belief in the exemption.

Conclusion:
The Tribunal set aside the impugned orders, holding that the IV Cannula manufactured by the appellant were covered by the exemption entry in List 37 of Notification No. 21/02-CUS. The appeals were allowed, and the duty demands were quashed. The Tribunal emphasized that the interpretation of the exemption entry in the Saberwal Surgical case, affirmed by the Supreme Court, was a binding precedent, and the denial of cross-examination of the DGHS official had vitiated the proceedings.

---